What is an FDA Form 483?

A Form FDA 483 lists an FDA investigator’s written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.

Does this Form 483 mean Vera Therapeutics, Inc. violated the law?

No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

What happens after a Form 483 is issued?

Argus HQ has recorded 2 total FDA actions tied to Vera Therapeutics, Inc.. The firm typically has 15 business days to submit a written response describing planned corrections; unresolved or serious findings can lead to a Warning Letter or other enforcement action.

Has Vera Therapeutics, Inc. had other FDA inspection citations?

Yes. Argus HQ has recorded 2 total FDA actions tied to Vera Therapeutics, Inc., including 1 Form 483 inspection citation.

March 2, 2026 FDA Form 483 for Vera Therapeutics, Inc.

Key facts

Firm	Vera Therapeutics, Inc.
FEI / inspection ID	3037451774
Inspection end date	March 2, 2026
Citation count	1

In short: FDA inspected Vera Therapeutics, Inc. in California, USA and issued a Form 483 listing 1 inspectional observation following an inspection that concluded 2026-03-02. FDA records classify Vera Therapeutics, Inc. as a sponsor. A Form 483 documents an investigator's findings at the close of an inspection under the Federal Food, Drug, and Cosmetic Act; it is not a final agency compliance determination. The observations on this page are drawn directly from the FDA-issued Form 483 record. A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

What a Form 483 means

A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

Citations explained

Observation 1 — -- 1 of 3 -- -- 2 of 3 -- The observations of objectionable conditions and practices

-- 1 of 3 -- -- 2 of 3 -- The observations of objectionable conditions and practices listed on the front of this form are reported: 1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or 2. To assist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration. Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides: "Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary." -- 3 of 3 -- A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

VERA THERAPEUTICS INC.’s FDA history

Argus HQ has recorded 2 total FDA actions tied to VERA THERAPEUTICS INC.: 0 warning letters, 0 recalls, 1 approval record, and 1 Form 483 inspection citation.

Frequently asked questions

What is an FDA Form 483?: A Form FDA 483 lists an FDA investigator’s written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.
Does this Form 483 mean Vera Therapeutics, Inc. violated the law?: No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.
What happens after a Form 483 is issued?: Argus HQ has recorded 2 total FDA actions tied to Vera Therapeutics, Inc.. The firm typically has 15 business days to submit a written response describing planned corrections; unresolved or serious findings can lead to a Warning Letter or other enforcement action.
Has Vera Therapeutics, Inc. had other FDA inspection citations?: Yes. Argus HQ has recorded 2 total FDA actions tied to Vera Therapeutics, Inc., including 1 Form 483 inspection citation.

See if this 483 escalates to a warning letter — before your auditor asks.

Free weekly briefing tracks every FDA inspection outcome.

Full FDA history for VERA THERAPEUTICS INC.

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). March 2, 2026 FDA Form 483 for Vera Therapeutics, Inc. — 1 Citations. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/483/vera-therapeutics-3037451774-2026-03-02

MLA

"March 2, 2026 FDA Form 483 for Vera Therapeutics, Inc. — 1 Citations." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/483/vera-therapeutics-3037451774-2026-03-02.

Chicago

Argus HQ Research. "March 2, 2026 FDA Form 483 for Vera Therapeutics, Inc. — 1 Citations." Digital Empire Holdings LLC. Accessed September 9, 2026. https://argushq.ai/483/vera-therapeutics-3037451774-2026-03-02.

BibTeX

@misc{argushq_argushq_ai_483_vera_therapeutics_3037451774_2026_03_02_2026,
  title = {March 2, 2026 FDA Form 483 for Vera Therapeutics, Inc. — 1 Citations},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/483/vera-therapeutics-3037451774-2026-03-02},
  note = {Accessed: September 9, 2026}
}

Source: FDA.gov — Inspection Classification Database ↗